IMARC Group has recently released a new research study titled “United States Biologics Market Size, Share, Trends and Forecast by Source, Product, Disease, Manufacturing and Region 2026-2034”, offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends and competitive landscape to understand the current and future market scenarios.

United States Biologics Market Overview 2026

The United States biologics market size reached USD 204.4 Billion in 2025. Looking ahead, IMARC Group projects the market to grow to USD 386.2 Billion by 2034, registering a CAGR of 7.11% during 2026–2034. Market growth is primarily driven by the rapid adoption of bioprocessing technologies for efficiency, growing expansion of biosimilars addressing affordability, and rising AI integration in drug discovery, clinical trials, and manufacturing. According to the CDC, an estimated 129 Million Americans have at least one chronic disease, with chronic diseases accounting for 90% of the annual USD 4.1 Trillion healthcare expenditure, highlighting the need for innovative biologics and strengthening the United States biologics market share.

In 2026, the United States biologics market is experiencing significant transformation as pharmaceutical and biotech companies adapt to changing patient needs and technological advancements. Businesses are increasingly implementing advanced bioprocessing technologies, single-use bioreactors, and continuous manufacturing systems to improve production efficiency and scalability. The growing popularity of biosimilars, personalized medicine, and AI-powered drug discovery is fueling United States biologics market demand. Moreover, the integration of artificial intelligence, advanced manufacturing capabilities, and supportive FDA frameworks such as fast-track approvals is improving patient access, treatment outcomes, and innovation, supporting the market's long-term growth.

Key Market Statistics at a Glance

• Base Year: 2025
• Historical Years: 2020–2025
• Forecast Period: 2026–2034
• Market Size (2025): USD 204.4 Billion
• Projected Size (2034): USD 386.2 Billion
• Growth Rate: CAGR of 7.11%

Analyze the United States Biologics Market Download the IMARC Sample Report for Insights: https://www.imarcgroup.com/united-states-biologics-market/requestsample

United States Biologics Market Trends and Growth Opportunities

The biologics industry in the United States is undergoing significant transformation, driven by changing patient needs and rapid technological advancements. One of the key United States biologics market trends is the growing adoption of advanced bioprocessing technologies, including single-use bioreactors, continuous manufacturing, and high-throughput screening systems that streamline production processes. Rentschler Biopharma's Milford facility, operational since July 2024 with four 2,000L single-use bioreactors, doubled cGMP capacity for complex biologics, supporting innovative therapies and reducing production costs while maintaining high-quality standards.

The rapid expansion of the biosimilars market continues to create new opportunities for companies across the country, given the growing demand for affordable alternatives to branded biologics. The FDA's Biosimilar Approval Pathway has allowed easier market entry and increased competition while decreasing treatment costs, making biologic therapies more accessible for chronic diseases like cancer and autoimmune disorders. For example, in July 2024, Sobi began a rolling BLA submission for SEL-212, a novel biologic aimed at serum urate levels in chronic refractory gout, reflecting continued investment in biosimilar research and development as patents for existing biologics expire.

The United States biologics market growth is also supported by the ongoing integration of artificial intelligence in biologics development, transforming drug discovery, clinical trial optimization, and manufacturing processes. AI-powered platforms analyze enormous datasets to identify promising biologic candidates, streamline patient recruitment, monitor real-time trial data, and predict outcomes, improving trial efficiency and success rates. Furthermore, investments in quality control monitoring, predictive maintenance, and workflow optimization through AI algorithms are expected to unlock new innovations and create long-term growth opportunities for the market during the forecast period.

Speak to an Analyst: https://www.imarcgroup.com/request?type=report&id=20441&flag=C

United States Biologics Market Detailed Segment Analysis

Breakup by Source:

• Microbial: Serves as an efficient host system for producing recombinant proteins, enzymes, and vaccines, offering rapid growth rates and cost-effectiveness for large-scale production.
• Mammalian: Critical for producing complex biologics such as monoclonal antibodies, fusion proteins, and cell therapies, with CHO cells dominating this segment.
• Others: Includes emerging production systems supporting specialized biologic manufacturing needs.

Breakup by Product:

• Monoclonal Antibodies: A mainstay of the market, widely used for cancer, autoimmune diseases, and infections with highly targeted therapeutic mechanisms.
• Vaccines: Growing rapidly, driven by advancements in mRNA technology and emphasis on pandemic preparedness and personalized vaccines.
• Recombinant Proteins: Widely used in treating diabetes, anemia, and growth disorders, with innovations in protein engineering enhancing therapeutic efficacy.
• Antisense, RNAi and Molecular Therapy: Represents advanced molecular-level treatment approaches addressing genetic and rare disease conditions.
• Others: Includes additional biologic product categories serving diverse therapeutic applications.

Breakup by Disease:

• Oncology: Leads the market given the significant occurrence of cancer and rising need for targeted treatments including monoclonal antibodies and immune checkpoint inhibitors.
• Immunological Disorders: Witnessing strong growth with rising incidence of diseases like rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
• Cardiovascular Disorders: Gaining ground through innovative treatments such as PCSK9 inhibitors for cholesterol regulation.
• Hematological Disorders: Includes biologics addressing blood-related conditions and disorders.
• Others: Includes additional disease areas benefiting from biologic therapy advancements.

Breakup by Manufacturing:

• Outsourced: Increasing as companies rely on contract research and manufacturing organizations for cost-efficient, scalable production.
• In-House: Remains vital for companies prioritizing control over manufacturing processes, quality assurance, and intellectual property.

Breakup by Region:

• Northeast: Driven by a concentration of leading biotechnology and pharmaceutical companies, particularly in Massachusetts and New York.
• Midwest: Growing rapidly in biologics manufacturing, with significant contributions from Illinois and Indiana.
• South: Strong market supported by major biopharmaceutical companies and favorable business climates in states like North Carolina and Texas.
• West: Dominates biologics innovation, particularly in California, home to Silicon Valley's biotechnology companies and research institutions.

Competitive Landscape

The United States biologics market is highly competitive, with leading biopharmaceutical companies focusing on the development of innovative biologics, biosimilars, and targeted therapies. Market participants are investing heavily in research and development, advanced biomanufacturing technologies, and strategic collaborations to strengthen their product portfolios. Continuous regulatory approvals, acquisitions, and expanding production capacities are further intensifying competition, while companies leverage precision medicine and next-generation biologics to enhance patient outcomes and increase market share.

Top Companies Operating in the United States Biologics Market

• Amgen Inc.: Develops innovative biologic therapies for oncology, immunology, cardiovascular diseases, and rare medical conditions.
• AbbVie Inc.: Offers leading biologic medicines focused on immunology, oncology, neuroscience, and autoimmune disease treatment.
• Johnson & Johnson: Provides advanced biologic therapies through continuous research, innovation, and a broad pharmaceutical portfolio.
• Pfizer Inc.: Expands biologics portfolio with innovative vaccines, biosimilars, and targeted therapies for chronic and infectious diseases.

Author IMARC Group

IMARC Group is a leading global market research company providing data-driven insights and expert consulting services to businesses seeking to achieve their strategic objectives. With a multidisciplinary team of industry experts, IMARC delivers reliable market intelligence across sectors including Chemicals and Materials, Healthcare, Technology, Agriculture, and Retail.

Contact Us:

IMARC Group

Email: sales@imarcgroup.com

United States: +1-201971-6302